- Home
- NRIX vs HBNC Comparison
NRIX vs HBNC Comparison
Compare NRIX & HBNC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRIX
- HBNC
- Stock Information
- Founded
- NRIX 2009
- HBNC 1873
- Country
- NRIX United States
- HBNC United States
- Employees
- NRIX N/A
- HBNC N/A
- Industry
- NRIX Biotechnology: Pharmaceutical Preparations
- HBNC Major Banks
- Sector
- NRIX Health Care
- HBNC Finance
- Exchange
- NRIX Nasdaq
- HBNC Nasdaq
- Market Cap
- NRIX 750.4M
- HBNC 826.6M
- IPO Year
- NRIX 2020
- HBNC N/A
- Fundamental
- Price
- NRIX $16.85
- HBNC $16.33
- Analyst Decision
- NRIX Strong Buy
- HBNC Buy
- Analyst Count
- NRIX 14
- HBNC 3
- Target Price
- NRIX $26.29
- HBNC $19.67
- AVG Volume (30 Days)
- NRIX 1.8M
- HBNC 298.3K
- Earning Date
- NRIX 10-09-2025
- HBNC 10-22-2025
- Dividend Yield
- NRIX N/A
- HBNC 3.91%
- EPS Growth
- NRIX N/A
- HBNC N/A
- EPS
- NRIX N/A
- HBNC N/A
- Revenue
- NRIX $83,687,000.00
- HBNC N/A
- Revenue This Year
- NRIX $58.48
- HBNC $51.78
- Revenue Next Year
- NRIX N/A
- HBNC $7.40
- P/E Ratio
- NRIX N/A
- HBNC N/A
- Revenue Growth
- NRIX 48.32
- HBNC 1.91
- 52 Week Low
- NRIX $8.18
- HBNC $12.70
- 52 Week High
- NRIX $23.09
- HBNC $19.18
- Technical
- Relative Strength Index (RSI)
- NRIX 80.15
- HBNC 57.83
- Support Level
- NRIX $12.43
- HBNC $15.47
- Resistance Level
- NRIX $13.43
- HBNC $16.16
- Average True Range (ATR)
- NRIX 0.97
- HBNC 0.36
- MACD
- NRIX 0.32
- HBNC 0.01
- Stochastic Oscillator
- NRIX 98.68
- HBNC 89.39
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.
About HBNC Horizon Bancorp Inc.
Horizon Bancorp (IN) is a United States-based holding company providing banking services. It is engaged in providing commercial and retail banking services, corporate and individual trust and agency services, and other services incident to banking. The company also provides commercial loans, real estate loans, mortgage warehouse loans, consumer loans, and other credit facilities. The company has one principal business segment, commercial banking.